WO1996039147A3 - Compositions ophtalmiques topiques contenant des derives de doxepine destinees au traitement d'affections allergiques des yeux - Google Patents

Compositions ophtalmiques topiques contenant des derives de doxepine destinees au traitement d'affections allergiques des yeux Download PDF

Info

Publication number
WO1996039147A3
WO1996039147A3 PCT/US1996/006289 US9606289W WO9639147A3 WO 1996039147 A3 WO1996039147 A3 WO 1996039147A3 US 9606289 W US9606289 W US 9606289W WO 9639147 A3 WO9639147 A3 WO 9639147A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye diseases
topical ophthalmic
ophthalmic formulations
treating allergic
formulations containing
Prior art date
Application number
PCT/US1996/006289
Other languages
English (en)
Other versions
WO1996039147A2 (fr
Inventor
John Michael Yanni
Stella M Robertson
Eiji Hayakawa
Masashi Nakakura
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23864859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996039147(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE2002199034 priority Critical patent/DE10299034I2/de
Priority to AT96915500T priority patent/ATE220906T1/de
Priority to DE69622527T priority patent/DE69622527T2/de
Priority to EP96915500A priority patent/EP0799044B1/fr
Priority to CA002195094A priority patent/CA2195094C/fr
Priority to JP9500510A priority patent/JP3068858B2/ja
Priority to MX9701013A priority patent/MX9701013A/es
Priority to KR1019970700721A priority patent/KR100202155B1/ko
Priority to DK96915500T priority patent/DK0799044T3/da
Priority to AU57261/96A priority patent/AU698854B2/en
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of WO1996039147A2 publication Critical patent/WO1996039147A2/fr
Priority to NO19970517A priority patent/NO311637B1/no
Priority to FI970489A priority patent/FI970489A0/fi
Publication of WO1996039147A3 publication Critical patent/WO1996039147A3/fr
Priority to NL300101C priority patent/NL300101I2/nl
Priority to LU90969C priority patent/LU90969I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Cette invention concerne des compositions ophtalmiques topiques contenant, en qualité d'ingrédient actif, de l'acide 11-(3-diméthylaminopropylidène)-6,11-dihydrodibenz[b,e]oxépin-2-acétique, ou un de ses sels acceptable sur le plan pharmaceutique. Ces compositions sont utiles dans le traitement d'affections allergiques des yeux, telles que la conjonctivite allergique, la conjonctivite printanière, la kératoconjonctivite printanière, et la conjonctivite papillaire géante.
PCT/US1996/006289 1995-06-06 1996-05-03 Compositions ophtalmiques topiques contenant des derives de doxepine destinees au traitement d'affections allergiques des yeux WO1996039147A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1019970700721A KR100202155B1 (ko) 1995-06-06 1996-05-03 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제
AU57261/96A AU698854B2 (en) 1995-06-06 1996-05-03 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
DK96915500T DK0799044T3 (da) 1995-06-06 1996-05-03 Topiske oftalmologiske formuleringer indeholdende olopatidin til behandling af allergiske øjensygdomme
EP96915500A EP0799044B1 (fr) 1995-06-06 1996-05-03 Compositions ophtalmiques topiques contenant olopatadine destinees au traitement d'affections allergiques des yeux
AT96915500T ATE220906T1 (de) 1995-06-06 1996-05-03 Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen
JP9500510A JP3068858B2 (ja) 1995-06-06 1996-05-03 アレルギー性眼疾患を処置するためのドキセピン誘導体を含有する局所的眼科用処方物
MX9701013A MX9701013A (es) 1995-06-06 1996-05-03 Formulaciones oftalmicos topicas que contienen derivador de doxepina para tratamiento de enfermedades oculares alergicas.
DE2002199034 DE10299034I2 (de) 1995-06-06 1996-05-03 Formulierung zur topischen Anwendung am Auge, die Olopatadine enthalten, zur Behandlung von allergischen Augenerkrankungen.
DE69622527T DE69622527T2 (de) 1995-06-06 1996-05-03 Formulierung zur topischen anwendung am auge, die olopatadine enthalten, zur behandlung von allergischen augenerkrankungen
CA002195094A CA2195094C (fr) 1995-06-06 1996-05-03 Compositions ophtalmiques topiques contenant des derives de doxepine destinees au traitement d'affections allergiques des yeux
FI970489A FI970489A0 (fi) 1995-06-06 1997-02-05 Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät doksepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon
NO19970517A NO311637B1 (no) 1995-06-06 1997-02-05 Topiske oftalmiske formuleringer inneholdende doxepinderivater for behandling av öyenallergisykdommer
NL300101C NL300101I2 (nl) 1995-06-06 2002-09-19 Topisch ofthalmische formuleringen die olopatadinebevatten voor het
LU90969C LU90969I2 (fr) 1995-06-06 2002-10-02 Compositions ophtalmiques topiques contenant olopatadine destinees au tritement d'affections allergiques des yeux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,729 US5641805A (en) 1995-06-06 1995-06-06 Topical ophthalmic formulations for treating allergic eye diseases
US08/469,729 1995-06-06

Publications (2)

Publication Number Publication Date
WO1996039147A2 WO1996039147A2 (fr) 1996-12-12
WO1996039147A3 true WO1996039147A3 (fr) 1997-02-20

Family

ID=23864859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/006289 WO1996039147A2 (fr) 1995-06-06 1996-05-03 Compositions ophtalmiques topiques contenant des derives de doxepine destinees au traitement d'affections allergiques des yeux

Country Status (20)

Country Link
US (1) US5641805A (fr)
EP (1) EP0799044B1 (fr)
JP (1) JP3068858B2 (fr)
KR (1) KR100202155B1 (fr)
CN (1) CN1082367C (fr)
AT (1) ATE220906T1 (fr)
AU (1) AU698854B2 (fr)
CA (1) CA2195094C (fr)
DE (2) DE69622527T2 (fr)
DK (1) DK0799044T3 (fr)
ES (1) ES2179198T3 (fr)
FI (1) FI970489A0 (fr)
LU (1) LU90969I2 (fr)
MX (1) MX9701013A (fr)
MY (1) MY116651A (fr)
NL (1) NL300101I2 (fr)
NO (1) NO311637B1 (fr)
PT (1) PT799044E (fr)
TW (1) TW438588B (fr)
WO (1) WO1996039147A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
KR100598723B1 (ko) * 1998-07-14 2006-07-11 알콘 매뉴팩츄어링, 리미티드 비알레르기성 안염증 질환 치료 및 안혈관신생 예방용약제를 제조하기 위한11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[β,ε]옥세핀-2-아세트산의 용도
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
CA2374002A1 (fr) 1999-06-18 2000-12-28 Alcon Laboratories, Inc. Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux
ATE291913T1 (de) 2000-01-25 2005-04-15 Alcon Inc Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen
CN1173697C (zh) 2000-05-19 2004-11-03 爱尔康公司 用于治疗过敏性疾病的苯胺二硫化物衍生物
CN1172666C (zh) 2000-05-19 2004-10-27 爱尔康公司 用于治疗过敏性疾病的含有苯甲酰胺二硫化物衍生物的组合物
AU5567501A (en) 2000-05-19 2001-12-03 Alcon Universal Ltd Disulfide derivatives useful for treating allergic diseases
AU2002316887A1 (en) * 2001-05-03 2002-11-18 Novartis Ag Anti-ige antibody to treat ocular allergies
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
BR0214643A (pt) * 2001-12-05 2004-11-03 Alcon Inc Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
US20050288283A1 (en) * 2004-06-28 2005-12-29 Alcon, Inc. Topical formulations for treating allergic diseases
CN103860540A (zh) * 2004-11-24 2014-06-18 爱尔康公司 奥洛他定在治疗鼻子过敏或发炎状态的制剂制备中的用途
ES2437077T3 (es) * 2005-07-08 2014-01-08 Senju Pharmaceutical Co., Ltd. Preparado oftálmico de absorción percutánea que comprende olopatadina
DK3150209T3 (da) 2006-03-31 2019-10-28 Vistakon Pharmaceuticals Llc Okulære allergibehandlinger
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
ES2781090T3 (es) 2007-02-07 2020-08-28 Novartis Ag Formulaciones de olopatadina para administración nasal tópica
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
US20100227917A1 (en) * 2007-09-06 2010-09-09 Masashi Nakakura EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
IT1397503B1 (it) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint Processo per la preparazione di olopatadina
MX2012000539A (es) * 2009-07-17 2012-02-28 Alcon Res Ltd Regimen de rocio nasal de olopatadina para niños.
WO2011027322A1 (fr) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Forme galénique à libération prolongée contenant de l'olopatadine pour une administration orale
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103202833A (zh) * 2012-12-25 2013-07-17 常州市亚邦医药研究所有限公司 一种奥洛他定或其盐的药用组合物及其制备方法
US20150119455A1 (en) * 2013-10-31 2015-04-30 Nephron Pharmaceuticals Corporation Formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0048023A2 (fr) * 1980-09-17 1982-03-24 Joel E. Bernstein, M.D. Composition pour le traitement et la prévention d'irritation oculaire
EP0214779A1 (fr) * 1985-08-17 1987-03-18 The Wellcome Foundation Limited Composés tricycliques
EP0235796A2 (fr) * 1986-03-03 1987-09-09 Kyowa Hakko Kogyo Co., Ltd. Dérivés de dibenzo[b,e]oxépine et agent anti-allergique et anti-inflammatoire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0048023A2 (fr) * 1980-09-17 1982-03-24 Joel E. Bernstein, M.D. Composition pour le traitement et la prévention d'irritation oculaire
EP0214779A1 (fr) * 1985-08-17 1987-03-18 The Wellcome Foundation Limited Composés tricycliques
EP0235796A2 (fr) * 1986-03-03 1987-09-09 Kyowa Hakko Kogyo Co., Ltd. Dérivés de dibenzo[b,e]oxépine et agent anti-allergique et anti-inflammatoire

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ATARASHII GANKA, vol. 11, no. 4, 1994, pages 603 - 5 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAMEI, CHIAKI ET AL: "Effects of certain anti-allergic drugs on experimental conjunctivitis in guinea pigs", XP002021562 *
KAMEI C ET AL: "Effect of (Z)-11-[3-(dimethylamino) propylidene]-6,11-dihydrodibenz[b,e ]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs.", ARZNEIMITTELFORSCHUNG, SEP 1995, 45 (9) P1005-8, GERMANY, XP000615221 *
OHSHIMA, ETSUO ET AL: "Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz(b,e)oxepin derivatives", J. MED. CHEM., 1992, 2074-84, XP000615220 *
SHARIF N A ET AL: "Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 278 (3). 1996. 1252-1261., XP000613049 *
SHARIF N A ET AL: "Olopatadine (AL-4943A): Pharmacological profile of a novel anti-histamine-anti-allergic drug for use in allergic conjunctivitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37 (3). 1996. S1027., XP000613434 *
SPITALNY L ET AL: "Olopatadine ophthalmic solution decreases itching and redness associated with allergic conjunctivitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37 (3). 1996. S593., XP000613433 *
YANNI J M ET AL: "The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic-antihistaminic agent", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37 (3). 1996. S1028., XP000613432 *
ZHANG M.-Q. ET AL: "Optically active analogues of ebastine: Synthesis and effect of chirality on their antihistaminic and antimuscarinic activity", CHIRALITY, 1994, 6/8 (631-641), USA, XP000613077 *

Also Published As

Publication number Publication date
DE10299034I2 (de) 2005-07-07
MX9701013A (es) 1997-05-31
KR100202155B1 (ko) 1999-06-15
DE69622527D1 (de) 2002-08-29
KR970704452A (ko) 1997-09-06
CA2195094A1 (fr) 1996-12-12
JP3068858B2 (ja) 2000-07-24
DE69622527T2 (de) 2002-12-05
MY116651A (en) 2004-03-31
DE10299034I1 (de) 2003-01-23
DK0799044T3 (da) 2002-10-14
FI970489A (fi) 1997-02-05
NO970517L (no) 1997-04-03
AU698854B2 (en) 1998-11-12
US5641805A (en) 1997-06-24
WO1996039147A2 (fr) 1996-12-12
JPH09510235A (ja) 1997-10-14
NL300101I1 (nl) 2002-12-02
NL300101I2 (nl) 2003-01-06
AU5726196A (en) 1996-12-24
CA2195094C (fr) 2002-02-26
LU90969I2 (fr) 2002-12-02
TW438588B (en) 2001-06-07
NO970517D0 (no) 1997-02-05
FI970489A0 (fi) 1997-02-05
NO311637B1 (no) 2001-12-27
ES2179198T3 (es) 2003-01-16
CN1161000A (zh) 1997-10-01
PT799044E (pt) 2002-11-29
EP0799044A2 (fr) 1997-10-08
EP0799044B1 (fr) 2002-07-24
ATE220906T1 (de) 2002-08-15
CN1082367C (zh) 2002-04-10

Similar Documents

Publication Publication Date Title
WO1996039147A3 (fr) Compositions ophtalmiques topiques contenant des derives de doxepine destinees au traitement d'affections allergiques des yeux
CA2216796A1 (fr) Derives de quinazoline
WO2001087329A8 (fr) Nouvelle composition pharmaceutique
CA2272584A1 (fr) Nouveaux derives de pyrazole substitues pour le traitement de maladies cardio-vasculaires
WO2001027111A3 (fr) Derives d'imidazo-3-yl-amine bicycliques
CA2107669A1 (fr) Preparation pour le traitement des lesions et des hemorroides
AU6199494A (en) New polypeptide compound and a process for preparation thereof
CA2306393A1 (fr) Utilisation d'acide 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz£b,e]oxepine-2-acetique dans la production d'un medicament de traitement de troubles ophtalmiques inflammatoires non allergiques et de prevention de la neoformation de vaisseaux sanguins oculaires
CA2190303A1 (fr) Composition pharmaceutique; methode et dispositif pour prevenir ou traiter le syndrome sec ou les maladies qui en decoulent
AU5910996A (en) Pyrrole derivatives and medicinal composition
WO2000078296A3 (fr) Tococotrienol et/ou derives de tocotrienol pour le traitement therapeutique ou prophylactique de troubles provoques par le glutamate et/ou le calcium
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
WO2001027110A3 (fr) Derives d'imidazo-3-yl-amine bicycliques substitues sur le sixieme chainon
EP0842663A4 (fr) Preparations ophtalmiques
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2320627A1 (fr) Medicaments contre les troubles cardio-diastoliques
CA2260863A1 (fr) Traitement de troubles d'ordre psychotique
AU7587396A (en) Ocular depressor
EP1172360A4 (fr) Potentialisateurs de la neurotrophine
AU1764300A (en) Novel derivatives of swainsonine, processes for their preparation, and their useas therapeutic agents
CA2340920A1 (fr) Procede prevenant l'apparition de l'asthme
WO1998038985A3 (fr) Medicament pour la prophylaxie et le traitement des maladies inflammatoires
AU2001270642A1 (en) Method for the treatment of glaucoma and ocular hypertension by administering nucleotides
WO1998038986A3 (fr) Medicament pour la prevention et la therapie d'infections virales
WO1999019324A3 (fr) Derives de piperidine substitues

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96190605.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN FI JP KR MX NO SG

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2195094

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1996915500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019970700721

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 970489

Country of ref document: FI

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN FI JP KR MX NO SG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1019970700721

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996915500

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970700721

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996915500

Country of ref document: EP